The IPO Buzz: Parabilis Medicines (PBLS) Prices Upsized IPO at $20 – Above Range & Stock Pops
Let’s do this again: Cancer biotech Parabilis Medicines (PBLS) upsized its IPO at pricing to 33.5 million shares – up from 33.33 million shares – and priced the deal at $20.00 – $1.00 above the top of its range – to raise $670 million on Tuesday night, June 9, 2026. It was the IPO’s second upsizing […]
June 10, 2026 Read More